Insulin Glargine Market: Size, Share, and Regional Outlook
Straits Research has published a comprehensive report on the global Insulin Glargine Market, providing in-depth insights into the market's current and future prospects. According to the report, the global Insulin Glargine market size was valued at USD 1290 Million in 2022 and is projected to reach from USD XX Million in 2023 to USD 2200 Million in 2031, growing at a CAGR of 6.11% during the forecast period (2023–2031).
Request a free request sample https://straitsresearch.com/report/insulin-glargine-market/request-sample
The Insulin Glargine market is experiencing significant growth due to the increasing prevalence of diabetes worldwide. The market is driven by factors such as the rising demand for long-acting insulin analogs, growing awareness about diabetes management, and the increasing adoption of insulin glargine biosimilars.
Market Segment Breakdown
The Insulin Glargine market is segmented based on type, including:
Lantus: Lantus is a long-acting insulin analog that is widely used for the treatment of type 1 and type 2 diabetes.
Basaglar: Basaglar is a long-acting insulin glargine biosimilar that is approved for the treatment of type 1 and type 2 diabetes.
Toujeo: Toujeo is a long-acting insulin glargine analog that is approved for the treatment of type 1 and type 2 diabetes.
Soliqua/Suliqua: Soliqua/Suliqua is a combination of insulin glargine and lixisenatide that is approved for the treatment of type 2 diabetes.
Insulin Glargine Biosimilars: Insulin glargine biosimilars are biological products that are highly similar to the reference product, Lantus.
Top Performing Companies
The top performing companies in the Insulin Glargine market include:
Novo Nordisk AS: Novo Nordisk AS is a Danish multinational pharmaceutical company that develops and markets insulin and other diabetes medications.
Sanofi Aventis: Sanofi Aventis is a French multinational pharmaceutical company that develops and markets insulin and other diabetes medications.
Biocon: Biocon is an Indian biopharmaceutical company that develops and markets insulin and other biopharmaceutical products.
Eli Lilly: Eli Lilly is an American pharmaceutical company that develops and markets insulin and other diabetes medications.
Julphar: Julphar is a UAE-based pharmaceutical company that develops and markets insulin and other diabetes medications.
Emerging Prospects
The Insulin Glargine market is expected to witness significant growth in the coming years, driven by emerging prospects such as:
Increasing adoption of insulin glargine biosimilars
Growing demand for long-acting insulin analogs
Rising awareness about diabetes management
Increasing investments in research and development of new insulin glargine products
This Report is available for purchase on https://straitsresearch.com/buy-now/insulin-glargine-market
Industry Movements
The Insulin Glargine market has witnessed several significant industry movements in recent years, including:
The launch of insulin glargine biosimilars such as Basaglar and Semglee
The approval of new insulin glargine products such as Toujeo and Soliqua/Suliqua
The increasing adoption of insulin glargine in emerging markets such as China and India
Geographic Analysis
The Insulin Glargine market is segmented into several regions, including North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to dominate the market during the forecast period, driven by the increasing prevalence of diabetes and the growing demand for long-acting insulin analogs.
Data Insights
The report provides comprehensive data insights into the Insulin Glargine market, including:
Market size and forecast
Market segmentation and analysis
Competitive landscape and company profiles
Emerging prospects and industry movements
Geographic analysis and regional insights
About Straits Research
Straits Research is a leading market research company that provides comprehensive and actionable insights into various industries. Our research reports are designed to provide valuable information and insights to help businesses make informed decisions.
Contact Us:
Email: [email protected]
Address: 825 3rd Avenue, New York, NY, USA, 10022
Tel: +1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
Email: [email protected]
Address: 825 3rd Avenue, New York, NY, USA, 10022
Tel: +1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)